- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01495975
Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control (DTTK)
Impact of a Web-based Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes affects 12-25% of all hospitalized adult patients, and 30% of hospitalized diabetes patients have one or more readmissions within one year. While glycemic control is rarely the primary reason for admission, poor glycemic control has been associated with increased rates of hospitalization and worse clinical outcomes, including infections, poor wound healing, and death. Hospitalization has been proposed as a "teachable moment" for patients with diabetes, as they have intensive contact with a full range of expert clinicians, but the effects of changes implemented during hospitalization after discharge are poorly studied.
The objective of this study is to conduct a randomized controlled trial to test a novel approach to diabetes management in the transition from inpatient to outpatient care. We will assign 40 hospitalized adult patients with type 2 diabetes to usual care or access to a web-based patient-provider communication and remote glucose monitoring tool ("Diabetes Transitions Tool Kit"). Our aims are to evaluate feasibility of implementation of the tool as well as impact on post-discharge glycemic control, diabetes-related self-care and distress. We hypothesize that providing patients this web-based tool over a 4-week period after discharge to home will result in more effective glycemic control compared to usual care, and that patients with access to the "tool kit" will have a trend towards improved diabetes self-management and less diabetes-related distress. Feasibility and preliminary data from this pilot study will be the foundation for larger-scale interventions that may ultimately improve the delivery of diabetes care in the transition from hospital to home.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- English speaking and able to read English
- Diagnosis of type 2 diabetes (new and pre-existing)
- Hospital admission with endocrinology or inpatient diabetes management consult
- On insulin during hospitalization with plan for continuation upon discharge.
- Discharge planned for home.
- Access to the internet and an active email account throughout the 6-week study period.
Exclusion Criteria:
- Inability to connect to, navigate, and utilize the web-based system, or designate someone who is capable of using the system.
- No identifiable outpatient healthcare provider.
- Pregnancy, ruled out by urine hCG test after consent is obtained in all women who continue to have menstrual cycles.
- End-stage liver disease with prothrombin time >15 seconds and albumin <3 mg/dL.
- Hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose <60 mg/dL (tachycardia, diaphoresis, hunger, confusion, fatigue).
- Projected survival <1 year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
Usual care for diabetes in the 1 month after discharge.
|
|
Experimental: Diabetes Transitions Tool Kit
Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
|
Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic Control
Time Frame: 1 month from discharge
|
Mean patient-day weighted glucose (from glucometer downloads) over the 30 days after discharge
|
1 month from discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diabetes Distress
Time Frame: 1 month from discharge
|
Measured by the Problem Areas in Diabetes (PAID) Questionnaire
|
1 month from discharge
|
Diabetes Self-Management
Time Frame: 1 month from discharge
|
1 month from discharge
|
|
Unplanned Readmission or ED Visit
Time Frame: 1 month after discharge
|
Unplanned readmission to any hospital within 30 days of discharge.
Emergency department admission to any hospital within 30 days of discharge.
|
1 month after discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nancy J Wei, MD, Massachusetts General Hospital
- Principal Investigator: Deborah J Wexler, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011p-001573
- 5K23DK080228-05 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
AstraZenecaRecruiting
Clinical Trials on Diabetes Transitions Tool Kit
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH); Massachusetts General Hospital; Beth...Enrolling by invitationHIV-infection/AIDSUnited States
-
Massachusetts General HospitalCompletedDiabetes Mellitus, Type 2United States
-
Brigham and Women's HospitalMassachusetts General Hospital; Robert Wood Johnson Foundation; North Shore Medical...Completed
-
Vanderbilt UniversityCompletedVentilator Associated Pneumonia | Central Line-associated Bloodstream Infection (CLABSI)United States
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingPreDiabetes | Lifestyle, Healthy | Activation, Patient
-
Vertos Medical, Inc.Completed
-
University of California, San FranciscoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsRecruitingKidney Cancer | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Rectal Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Colon CancerUnited States
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Lara McKenzieCompletedIntervention-carbon Monoxide Alarm + Educational Tool | Control- Usual Care Flyer on Carbon MonoxideUnited States